January 25th 2024
The expanded indication makes dupilumab the only approved treatment for eosinophilic esophagitis (EoE) in this age group.
Turning Food Allergy Triggers Into Therapy: A Managed Care Lens on Immunotherapy and Targeted Biologics
1.5 Credits / Immunology
View More
Targeted Therapies for the Management of Eosinophilic Esophagitis Across the Life Cycle: The Role of the Pharmacist in Patient Identification and Optimization, featuring a Pat...
1.5 Credits / Immunology
View More
Managed Care Perspectives on the Burden of Food Allergies and Advances in Treatment
1.5 Credits / Allergy, Immunology
View More
Dr Jonathan Silverberg Sheds Light on the Shift in Comorbidities Associated With Atopic Dermatitis
May 14th 2021In order to properly help patients manage their disease, it is critical for clinicians to recognize the differences in prevalence, severity, and persistency of atopic dermatitis among different demographics, said Jonathan Silverberg, MD, PhD, MPH.
Watch
Asthma Exacerbations Declined Among Black and Hispanic Patients During COVID-19
May 12th 2021Asthma exacerbations among Black/African American and Hispanic/Latinx adults with moderate-to-severe asthma decreased by approximately 40% during the COVID-19 pandemic, particularly among individuals who worked outside the home and those without type 2 inflammation.
Read More
Dr Jonathan Silverberg on Why It's Crucial to Know How AD Prevalence Shifts Over Time
April 30th 2021As atopic dermatitis (AD) prevalence has increased in children over several decades, it's critical for physicians to recognize the environmental and demographic factors contributing to the change, said Jonathan Silverberg, MD, PhD, MPH.
Watch
Atopic Diseases Linked to Behavioral Difficulties in Children, Adolescents
April 29th 2021The study findings show that atopic dermatitis is associated with internalizing and externalizing problems, with younger children experiencing emotional problems and adolescents with other atopic diseases having relationship problems.
Read More
Patients With Lower SES or Uncontrolled Disease May Be More Likely to Stop Biologic Therapy
March 6th 2021Although 90% of patients with severe asthma choose to continue using a biologic, patients with worse disease control at baseline or with lower socioeconomic status (SES) may be more likely to cease biologic use, according to a poster presented at the American Academy of Allergy, Asthma & Immunology 2021 Annual Meeting.
Read More
Use of a Specialty Pharmacy Sped Time to PA Decisions for Dermatology Practice
February 27th 2021Use of a specialty pharmacy to take over the management of prior authorization (PA) requests for a dermatology practice significantly reduced the time to a decision and also decreased the time it took to fill the medication.
Read More
Publicly Insured Patients With Asthma Treated Less Often With Biologics
February 16th 2021Treatment of asthma with biologics was lower for those on public health insurance compared with those who had private insurance, with Blacks underrepresented relative to Whites in publicly insured visits where biologic treatment is used.
Read More
Assessing Disease Severity in AD, Psoriasis Through Transepidermal Water Loss, Temperature
February 2nd 2021Temperature and transepidermal water loss can serve as objective measures to help determine severity of cases of atopic dermatitis (AD) psoriasis and identify which patients need intensive treatment, according to a new study.
Read More
Study Compares Mepolizumab, Benralizumab for Eosinophilic Asthma
January 15th 2021Mepolizumab and benralizumab are both potent targets of the interlukin-5 pathway with the ability to significantly reduce eosinophil counts, according to new research published in Allergy, Asthma & Clinical Immunology.
Read More
What a Review Says About Biologics for Allergic Bronchopulmonary Aspergillosis, Asthma, CF
December 27th 2020The review of 32 studies revealed that biologic treatment tended to favor patients with allergic bronchopulmonary aspergillosis (ABPA) and asthma rather than those with cystic fibrosis (CF).
Read More
Patients With Atopic Dermatitis Report Broad Array of OOP Expenses Related to Disease
December 26th 2020In addition to significant morbidity and impaired health-related quality of life, patients with atopic dermatitis have a significant out-of-pocket (OOP) financial burden related to their disease.
Read More
Top 5 Most-Read Inflammation Articles of 2020
December 23rd 2020This year, the most popular articles and interviews related to the role of inflammation in asthma and other conditions touched on the mechanisms of inflammation, patterns of inhaler use, and the real-world impacts of the monoclonal antibody dupilumab.
Read More
Dr David Pariser Outlines Unmet Needs in Treatment Options for Atopic Dermatitis
December 18th 2020The treatment landscape for atopic dermatitis is beginning to change from the use of topical therapies to biologics and more, said David Pariser, MD, senior physician at Pariser Dermatology Specialists and professor at Eastern Virginia Medical School Department of Dermatology.
Watch
Older Adults Are Often Excluded From RCTs of Systemic Treatments for Atopic Dermatitis
December 17th 2020Older adults are often at greater risk for adverse events from treatments, but they can also be excluded from randomized controlled trials (RCTs), making it difficult to know if findings are generalizable to this population.
Read More
Guideline-Informed Care Among Medicaid-Enrolled Children With Food Allergy
This article describes food allergy–related service utilization and identifies factors associated with guideline-informed care among Medicaid-enrolled US children with food allergy.
Read More